Positive Phase III Alzheimer's results send Lundbeck and Otsuka shares skywards

27 June 2022

Danish firm Lundbeck (LUND: CO) and Japan’s Otsuka Pharmaceutical (TYO: 4578) brought some rare good news in a challenging disease as they announced positive results from a Phase III trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's-type dementia.

The analysis concluded that there is a statistically-significant difference in the mean change from baseline to week 12 in the Cohen-Mansfield Agitation Inventory total score between brexpiprazole and placebo.

Monday’s announcement sent shares in both companies sharply upwards. Lundbeck was more than 10% higher as Europe’s trading day entered its final third, while Otsuka finished up 5% in Tokyo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK